Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma
dc.contributor.author | Hensley, Martee L. | en_US |
dc.contributor.author | Wathen, J. Kyle | en_US |
dc.contributor.author | Maki, Robert G. | en_US |
dc.contributor.author | Araujo, Dejka M. | en_US |
dc.contributor.author | Sutton, Gregory | en_US |
dc.contributor.author | Priebat, Dennis A. | en_US |
dc.contributor.author | George, Suzanne | en_US |
dc.contributor.author | Soslow, Robert A. | en_US |
dc.contributor.author | Baker, Laurence H. | en_US |
dc.date.accessioned | 2013-05-02T19:35:12Z | |
dc.date.available | 2014-05-23T15:04:20Z | en_US |
dc.date.issued | 2013-04-15 | en_US |
dc.identifier.citation | Hensley, Martee L.; Wathen, J. Kyle; Maki, Robert G.; Araujo, Dejka M.; Sutton, Gregory; Priebat, Dennis A.; George, Suzanne; Soslow, Robert A.; Baker, Laurence H. (2013). "Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma ." Cancer 119(8): 1555-1561. <http://hdl.handle.net/2027.42/97490> | en_US |
dc.identifier.issn | 0008-543X | en_US |
dc.identifier.issn | 1097-0142 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/97490 | |
dc.description.abstract | BACKGROUND: Between 30% and 50% of women who have high‐grade uterine leiomyosarcoma (uLMS) limited to the uterus at diagnosis remain progression‐free at 2 years. Adjuvant pelvic radiation does not improve outcome. The objective of the current study was to determine the 2‐year and 3‐year progression‐free survival (PFS) among a prospective cohort of women who received adjuvant gemcitabine plus docetaxel followed by doxorubicin. METHODS: Women with uterus‐limited, high‐grade uLMS and adequate organ function were eligible. Within 12 weeks of complete resection and after confirmation that they had no evidence of disease on computed tomography (CT) images, the patients received 4 cycles of fixed‐dose‐rate gemcitabine plus docetaxel. Those who were confirmed disease‐free on CT scans after cycle 4 received 4 cycles of doxorubicin. CT imaging for recurrence was performed every 3 months for 2 years, then every 6 months for 3 years. RESULTS: In total, 47 women were enrolled (46 evaluable) in 3 years. Characteristics included a median age of 53 years; 1988 International Federation of Gynecology and Obstetrics stage I disease in 81% of patients, stage II disease in 15%, and serosa‐only stage IIIA disease in 4%; American Joint Committee on Cancer stage II disease in 13% of patients and stage III disease in 87%; a median tumor size of 8 cm (range, 2.5‐30 cm); and a median mitotic rate of 18 mitoses per 10 high‐power fields (range, 5‐83 mitoses per 10 high‐power fields). At a median follow‐up of 39.8 months, 21 of 46 patients developed recurrent disease (45.7%). The median time to recurrence was 27.4 months (range, 3‐40 months). Seventy‐eight percent of patients (95% confidence interval, 67%‐91%) were progression‐free at 2 years, and 57% (95% confidence interval, 44%‐74%) were progression‐free at 3 years. The median PFS was not reached and exceeded 36 months. CONCLUSIONS: Among women with high‐grade, uterus‐limited uLMS who received treatment with adjuvant gemcitabine plus docetaxel followed by doxorubicin, 78% remained progression‐free at 2 years, and 57% remained progression‐free at 3 years. A randomized trial of adjuvant chemotherapy versus observation to determine whether adjuvant chemotherapy can improve survival in women with uterus‐limited uLMS is underway. Cancer 2013. © 2013 American Cancer Society. Among women with high‐grade, uterus‐limited leiomyosarcoma who receive treatment with adjuvant gemcitabine plus docetaxel followed by doxorubicin, 78% remain progression‐free at 2 years, and 57% remain progression‐free at 3 years. | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Survival | en_US |
dc.subject.other | Leiomyosarcoma | en_US |
dc.subject.other | Uterine | en_US |
dc.subject.other | Chemotherapy | en_US |
dc.subject.other | Adjuvant | en_US |
dc.title | Adjuvant therapy for high‐grade, uterus‐limited leiomyosarcoma | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Public Health | en_US |
dc.subject.hlbsecondlevel | Oncology and Hematology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Hematology and Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Section of Hematology/Oncology, Washington Cancer Institute | en_US |
dc.contributor.affiliationother | Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan‐Kettering Cancer Center, New York, New York | en_US |
dc.contributor.affiliationother | Weill Cornell Medical College, New York, New York | en_US |
dc.contributor.affiliationother | Janssen Research and Development, LLC, Titusville, New Jersey | en_US |
dc.contributor.affiliationother | Pediatric Hematology/Oncology Division, Mt. Sinai Medical Center, New York, New York | en_US |
dc.contributor.affiliationother | Sarcoma Medical Oncology Division, University of Texas MD Anderson Cancer Center, Houston, Texas | en_US |
dc.contributor.affiliationother | Department of Surgery, Gynecologic Oncology, St. Vincent's Hospital, Indianapolis, Indiana | en_US |
dc.contributor.affiliationother | Department of Medical Oncology, Center for Sarcoma and Bone Oncology, Dana‐Farber Cancer Institute, Boston, Massachusetts | en_US |
dc.contributor.affiliationother | Department of Pathology, Memorial Sloan‐Kettering Cancer Center, New York, New York | en_US |
dc.contributor.affiliationother | Department of Medicine, Gynecologic Medical Oncology Service, Memorial Sloan‐Kettering Cancer Center, 300 East 66th Street, Suite 1355, New York, NY 10065 | en_US |
dc.identifier.pmid | 23335221 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/97490/1/27942_ftp.pdf | |
dc.identifier.doi | 10.1002/cncr.27942 | en_US |
dc.identifier.source | Cancer | en_US |
dc.identifier.citedreference | Dinh TA, Oliva EA, Fuller AF Jr, Lee H, Goodman A. The treatment of uterine leiomyosarcoma. Results from a 10‐year experience (1990‐1999) at the Massachusetts General Hospital. Gynecol Oncol. 2004; 92: 648 ‐ 652. | en_US |
dc.identifier.citedreference | Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009; 54: 355 ‐ 364. | en_US |
dc.identifier.citedreference | Pautier P, Floquet A, Gladieff L, et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin in localized uterine sarcomas: results from 81 randomized patients [abstract]. J Clin Oncol. 2011; 29 ( suppl ). Abstract 10022. | en_US |
dc.identifier.citedreference | Bell SW, Kempson RL, Hendrickson MR. Problematic uterine smooth muscle neoplasms. A clinicopathologic study of 213 cases. Am J Surg Pathol. 1994; 18: 535 ‐ 558. | en_US |
dc.identifier.citedreference | Sutton GP, Blessing JA, Barrett RJ, McGehee R. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol. 1992; 166: 556 ‐ 559. | en_US |
dc.identifier.citedreference | Omura GA, Major FJ, Blessing JA, et al. A randomized study of Adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983; 52: 626 ‐ 632. | en_US |
dc.identifier.citedreference | Look KY, Sandler A, Blessing JA, Lucci III JA, Rose PG. Phase II trial of gemcitabine as second‐line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) study. Gynecol Oncol. 2004; 92: 644 ‐ 647. | en_US |
dc.identifier.citedreference | Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley HD. Fixed‐dose rate gemcitabine plus docetaxel as second‐line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2008; 109: 323 ‐ 328. | en_US |
dc.identifier.citedreference | Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed‐dose rate gemcitabine plus docetaxel as first‐line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008; 109: 329 ‐ 334. | en_US |
dc.identifier.citedreference | Hensley ML, Ishill N, Soslow RA, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I‐IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol. 2009; 112: 563 ‐ 567. | en_US |
dc.identifier.citedreference | Odunsi K, Moneke V, Tammela J, et al. Efficacy of adjuvant CYVADIC chemotherapy in early stage uterine sarcomas: results of long‐term follow‐up. Int J Gynecol Cancer. 2004; 14: 659 ‐ 664. | en_US |
dc.identifier.citedreference | Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant Adriamycin in uterine sarcomas: a Gynecologic Oncology Group study. J Clin Oncol. 1985; 3: 1240 ‐ 1245. | en_US |
dc.identifier.citedreference | Pautier P, Rey A, Haie‐Meder C, et al. Adjuvant chemotherapy with cisplatin, ifosfamide, and doxorubicin followed by radiotherapy in localized uterine sarcomas: results of a case‐control study with radiotherapy alone. Int J Gynecol Cancer. 2004; 14: 1112 ‐ 1117. | en_US |
dc.identifier.citedreference | Wolfson A, Brady MF, Rocereto T, et al. A Gynecologic Oncology Group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin‐ifosfamide and mesna (CIM) as postsurgical therapy in stage I‐IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007; 107: 177 ‐ 185. | en_US |
dc.identifier.citedreference | Reed NS, Mangioni C, Malmstrom H, et al. European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: a European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008; 44: 808 ‐ 818. | en_US |
dc.identifier.citedreference | Wu TI, Chang TC, Hsueh S, et al. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma. Gynecol Oncol. 2006; 100: 166 ‐ 172. | en_US |
dc.identifier.citedreference | Pautier P, Genestie C, Rey A, et al. Analysis of clinicopathologic prognostic factors for 157 uterine sarcomas and evaluation of a grading score validated for soft tissue sarcoma. Cancer. 2000; 88: 1425 ‐ 1431. | en_US |
dc.identifier.citedreference | Giuntoli RL 2nd, Metzinger DS, DiMarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2003; 89: 460 ‐ 469. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.